Viridian Therapeutics Reports Third Quarter 2024 Financial Results ...

Filings - Quarterly Results - Viridian Therapeutics, Inc.

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data ; Change in unrealized gain on investments. 1,475.

This quarter, we also further strengthened our cash position with a financing that allows us to accelerate our R&D pipeline and extend our cash ...

Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat ...

Viridian Therapeutics ( NASDAQ:VRDN ) Third Quarter 2024 Results Key Financial Results Net loss: US$76.7m (loss widened...

Viridian Therapeutics Reports Third Quarter 2024 Financial Results ...

Viridian Therapeutics advances TED treatment with positive Phase 3 data, extends pipeline development, and strengthens financial position ...

Viridian Therapeutics, Inc. - Investors & Media

Latest News · November 12, 2024. Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data · November 5, 2024.

Viridian Therapeutics Reports Third Quarter 2024 Financial Results

This quarter, we also further strengthened our cash position with a financing that allows us to accelerate our R&D pipeline and extend our cash ...

Viridian Therapeutics Reports Third Quarter 2024 Financial Results ...

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data · Full name. Viridian Therapeutics ...

Viridian Therapeutics, Inc. on X: "Today, we reported Q3 2024 ...

Today, we reported Q3 2024 financial results and recent progress, including new FcRn portfolio data. Read the full update here: ...

News - Viridian Therapeutics, Inc.

November 12, 2024. Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data · November 5, 2024 · September ...

Vivos Therapeutics Reports Third Quarter 2024 Financial

Gross profit was $2.3 million for the third quarter of 2024 and $6.9 million for the nine months ended September 30, 2024, compared to $1.7 ...

Viridian Therapeutics Reports Third Quarter 2024 Financial Results ...

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data · Download · Smart Multimedia ...

Viridian Therapeutics, Inc. Reports Earnings Results for the Third ...

Viridian Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company ...

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue ...

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11.

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

Net revenue of $1.9 million for the nine months ended September 30, 2024 increased 89% compared to $1.0 million for same period in 2023. The ...

Viridian Therapeutics Reports Third Quarter 2023 Financial Results ...

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update ; Revenue: Collaboration Revenue - related party.

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results ...

Research and Development (R&D) Expenses were $19.2 million for the third quarter ended September 30, 2024 as compared to $19.1 million for the ...

Viridian Therapeutics Highlights Recent Progress and Reports ...

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results ; Research and development. 56,193 ; General ...

Viridian Therapeutics Reports Increased Cash Reserves Amid Losses

In its latest earnings report for the quarter ending September 30, 2024, Viridian Therapeutics highlighted a significant increase in cash ...

Checkpoint Therapeutics Reports Third Quarter 2024 Financial ...

General and administrative expenses for the third quarter of 2024 included $1.4 million of non-cash stock expenses, compared to $0.6 million for ...

News Details - Viridian Therapeutics, Inc.

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results ; Revenue: Collaboration Revenue ...